The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
Open accessAbstract
BACKGROUND: Roflumilast is a targeted oral once-daily administered phosphodiesterase 4 (PDE4) inhibitor with clinical efficacy in chronic obstructive pulmonary disease (COPD). Results from in vitro studies with roflumilast indicate that it has anti-inflammatory properties that may be applicable for the treatment of COPD. METHODS: In a crossover study, 38 patients with COPD (mean (SD) age 63.1 (7.0) years, post-bronchodilator forced expiratory volume in 1 s (FEV(1)) 61.0 (12.6)% predicted) received 500 microg roflumilast or placebo once daily for 4 weeks. Induced sputum samples were collected before and after 2 and 4 weeks of treatment. Differential and absolute cell counts were determined in whole sputum samples. Markers of inflammation were determined in sputum supernatants and blood. Spirometry was performed weekly. RESULTS: Roflumilast significantly reduced the absolute number of neutrophils and eosinophils/g sputum compared with placebo by 35.5% (95% CI 15.6% to 50.7%; p = 0.002) and 50.0% (95% CI 26.8% to 65.8%; p<0.001), respectively. The relative proportion of sputum neutrophils and eosinophils was not affected by treatment (p>0.05). Levels of soluble interleukin-8, neutrophil elastase, eosinophil cationic protein and alpha(2)-macroglobulin in sputum and the release of tumour necrosis factor alpha from blood cells were significantly reduced by roflumilast compared with placebo treatment (p<0.05 for all). Post-bronchodilator FEV(1) improved significantly during roflumilast compared with placebo treatment with a mean difference between treatments of 68.7 ml (95% CI 12.9 to 124.5; p = 0.018). CONCLUSION: PDE4 inhibition by roflumilast treatment for 4 weeks reduced the number of neutrophils and eosinophils, as well as soluble markers of neutrophilic and eosinophilic inflammatory activity in induced sputum samples of patients with COPD. This anti-inflammatory effect may in part explain the concomitant improvement in post-bronchodilator FEV(1).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Lung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Self-citationGlobal Initiative for Chronic Obstructive Lung Disease (GOLD)
Rahman, M. M., & Siddiqui, M. M. R. (2017) · Anwer Khan Modern Medical College Journal · doi:10.3329/akmmcj.v7i1.31596 · Cited by 3,106
Standardization of Spirometry—1987 Update
(1987) · American Review of Respiratory Disease · doi:10.1164/ajrccm/136.5.1285 · Cited by 2,315
Gan, W. Q. (2004) · Thorax · doi:10.1136/thx.2003.019588 · Cited by 1,838
Siafakas, N., Vermeire, P., Pride, N., Paoletti, P., Gibson, J., Howard, P., Yernault, J., Decramer, M., Higenbottam, T., Postma, D., et al. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081398 · Cited by 1,592
Keatings, V. M., Collins, P. D., Scott, D. M., & Barnes, P. J. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.2.8564092 · Cited by 1,362
Pathophysiology of airflow limitation in chronic obstructive pulmonary disease
Hogg, J. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16900-6 · Cited by 1,294
Cited by
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Calverley, P. M., Rabe, K. F., Goehring, U.-M., Kristiansen, S., Fabbri, L. M., & Martinez, F. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61255-1 · Cited by 829
Self-citationNew insights into the immunology of chronic obstructive pulmonary disease
Brusselle, G. G., Joos, G. F., & Bracke, K. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60988-4 · Cited by 776
Fabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61252-6 · Cited by 614
Self-citationPDE4 inhibitors: current status
Spina, D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.307 · Cited by 340
Metadata
- Authors
- Grootendorst, D. C., Gauw, S. A., Verhoosel, R. M., Sterk, P. J., Hospers, J. J., Bredenbroker, D., Bethke, T. D., Hiemstra, P. S., & Rabe, K. F.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2007-12-01
- Volume
- 62
- Issue
- 12
- Pages
- 1081-1087
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2026549814
- Cited by
- 286
- References
- 36
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. https://app.cochat.ai/papers/10.1136/thx.2006.075937
- The paper
- Grootendorst, D. C., Gauw, S. A., Verhoosel, R. M., Sterk, P. J., Hospers, J. J., Bredenbroker, D., Bethke, T. D., Hiemstra, P. S., & Rabe, K. F. (2007). Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. https://doi.org/10.1136/thx.2006.075937
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.